<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518761</url>
  </required_header>
  <id_info>
    <org_study_id>TOFPROS02</org_study_id>
    <nct_id>NCT04518761</nct_id>
  </id_info>
  <brief_title>Predictive Modelling of the Intraoperative Train-of-Four (TOF) Ratio</brief_title>
  <official_title>Predictive Modelling of the Intraoperative Train-of-Four (TOF) Ratio</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuromuscular Blocking Agents (NMBAs) are routinely administered to patients in a&#xD;
      multiplicity o anaesthetic settings in order to paralyze and impede (re)active muscular&#xD;
      contraction. The availability of monitoring devices allowing an accurate measurement fo the&#xD;
      degree of neuromuscular block during anesthesia has raised the standards for a proper&#xD;
      evidence-based use of NMBAs.&#xD;
&#xD;
      For this purpose, one of the most widely used methods is the Train of Four (TOF):&#xD;
      transcutaneous application of a series of 4 square-wave supra-maximal electrical stimuli over&#xD;
      the course of a nerve of choice (most commonly the ulnar nerve). These are applied at a&#xD;
      frequency of 2Hz, and each with a duration of 0.2ms. These stimuli elicit a motor response on&#xD;
      the adductor pollicis muscle, which on its turn dictates the adduction of the thumb. The&#xD;
      acceleration of this movement can be followed by means of an uni/multi-directional&#xD;
      accelerometer attached to the thumb. The ratio of the acceleration of the 4th and 1st&#xD;
      elicited contractions is called the TOF-Ratio - a clinically and scientifically established&#xD;
      method of assessing neuromuscular block recovery. A value of 1 translates a full recovery of&#xD;
      the muscular function of a patient. In modern Anesthesia, the bar for deeming a recovery as&#xD;
      adequate has been set at a minimum of a TOF-ratio of &gt;0.9, with some authors advocating a&#xD;
      ratio of 1 as the only acceptable and complications avoiding result.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Days</target_duration>
  <primary_outcome>
    <measure>TOF-ratio</measure>
    <time_frame>1 day</time_frame>
    <description>Train of four percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TOF-count</measure>
    <time_frame>1 day</time_frame>
    <description>Train of four count</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Analyse Neuromuscular Monitoring for Developing a Model to Predict TOF Ratio During Anesthesia</condition>
  <arm_group>
    <arm_group_label>Prospective group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Elective surgery</intervention_name>
    <description>Any patient who needs to undergo an elective surgery.</description>
    <arm_group_label>Prospective group</arm_group_label>
    <arm_group_label>Retrospective group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (18 years old and above) receiving General Anesthesia for noncardiac surgery&#xD;
        requiring the use of a neuromuscular blocking agent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (18 years old and above) receiving General Anesthesia for noncardiac&#xD;
             surgery requiring the use of a neuromuscular blocking agent.&#xD;
&#xD;
          -  Administration of General Anesthesia by means of Total Intravenous Anesthesia&#xD;
             technique.&#xD;
&#xD;
          -  Use of Rocuronium as a neuromuscular blocking agent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of different types of neuromuscular blocking agents for the same patient within&#xD;
             the same surgical procedure&#xD;
&#xD;
          -  Known Neuromuscular diseases/syndromes judged to condition accurate neuromuscular&#xD;
             monitoring.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussel</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelien Vandeurzen, Biomedical Sciences</last_name>
      <phone>024749237</phone>
      <email>evelien.vandeurzen@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Hugo Carvalho, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Publication via medical article.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

